EGFR and non-small cell lung carcinoma: Several other studies also showed that bevacizumab plus EGFR-TKIs significantly prolonged PFS with acceptable toxicity profile than EGFR-TKI monotherapy for patients with EGFR-mutant NSCLC [12, 16, 17].